When will the patents on ZINC CHLORIDE IN PLASTIC CONTAINER expire, and when will ZINC CHLORIDE IN PLASTIC CONTAINER go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	ZINC CHLORIDE IN PLASTIC CONTAINER	zinc chloride	INJECTABLE;INJECTION	018959-001	Jun 26, 1986	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 18, 2026

Zinc Chloride in Plastic Container: Investment Scenario, FDA/Orange Book Status, and IP Risk Fundamentals

Executive summary: Zinc chloride packaged in plastic containers is a low-value, high-regulatory/packaging-dependent product with limited patent depth typical of commodity topical/industrial zinc salts. The investment case is driven by (1) FDA-market access classification (drug vs. non-drug use), (2) container-closure system performance requirements, and (3) exclusivity and patentability of the specific formulation/manufacturing/process and labeling. Absent a clearly defined FDA-approved drug listing tied to a specific NDA (and its patent/exclusivity records), there is no defensible basis to underwrite material patent-protected revenue. The practical risk profile is “supply chain plus compliance,” not “IP moat.”

Is zinc chloride in plastic container an FDA-approved drug product with Orange Book patents?

Featured snippet answer: Investment-grade patent and exclusivity analysis for “zinc chloride in plastic container” requires a specific FDA application (NDA/ANDA/BLA) and associated Orange Book listings. Without a uniquely tied FDA record, patent estates typically cannot be mapped to the exact product and packaging.

Drug vs. non-drug classification: what investors must verify

Key decision point is whether the product is marketed as:

A drug (intended for diagnosis, cure, mitigation, treatment, or prevention of disease) with an NDA/ANDA listing
A commodity/industrial chemical (where FDA drug exclusivity and Orange Book frameworks typically do not apply)

If the product is not an FDA-approved drug product, investment fundamentals shift from patent litigation to:

Chemical sourcing and quality systems (GMP-like controls)
Regulatory compliance for labeling and intended use
Packaging compatibility and shelf-life documentation

Orange Book status depends on the NDA

Orange Book listings attach to a specific applicant’s NDA and NDC(s). For “zinc chloride in plastic container,” the investor thesis must map to:

NDA number
listed NDCs
container-closure system (plastic type, cap/liner, extractables/leachables)
strength and dosage form (solution, topical, oral, etc.)

What patents protect zinc chloride drug products in plastic containers?

Featured snippet answer: Patent protection, when present, usually centers on the specific formulation, concentration range, container-closure compatibility, and manufacturing process rather than on zinc chloride itself, which is a known inorganic compound.

Where patent coverage typically concentrates

For zinc chloride products, common patent categories that can create defensible value:

Formulation patents
- Stabilizers, buffering agents, complexing agents
- Preservatives and pH control to maintain stability and avoid precipitation/corrosion
Method-of-manufacture patents
- Controlled crystallization/solution preparation steps
- Filtration, sterilization, and packaging line steps
Container-closure system patents
- Plastic materials and liners chosen to reduce leaching
- Compatibility testing and extractables limits
Method-of-use patents
- Specific therapeutic use claims tied to clinical regimen, not the base chemical

What usually does not create an IP moat

Second-use claims without meaningful novelty
Packaging-only claims that are easy to design around with alternative plastic types
Broad chemical claims on zinc chloride itself, which is often difficult to enforce against generics that use the same API

How many patents cover zinc chloride in plastic container products, and who holds them?

Featured snippet answer: Patent count and assignee mapping require the specific FDA listing. In absence of a defined NDA/NDC record, the patent landscape can’t be quantified for the exact product packaged in plastic.

Investment implication of low patent counts

If Orange Book lists few or no patents, the product behaves like a:

Generic-like molecule with packaging and QC-driven differentiation
Low litigation intensity product class
Thin pricing power, limited by multiple suppliers and fast follow-ons

When does zinc chloride packaged in plastic lose exclusivity?

Featured snippet answer: Exclusivity timelines (3-year, 5-year, pediatric) apply to NDA/BLA holders with statutory eligibility tied to approval pathways. Without a defined NDA record, the exclusivity clock cannot be stated for “zinc chloride in plastic container” as a generic product description.

What to look for in exclusivity records

Five-year New Chemical Entity (NCE) exclusivity: unlikely for zinc chloride
Three-year new clinical studies exclusivity: possible if reformulated or new indication
Patent term adjustment (PTA) and pediatric exclusivity: can extend effective exclusivity
Orphan drug exclusivity: only if rare indication and designated

Investor takeaway

For commodity salts, the typical outcome is:

No meaningful statutory exclusivity
Limited patent term remaining or weak patentability of formulation/packaging details

What FDA regulatory pathway applies to zinc chloride in plastic container (NDA vs. ANDA)?

Featured snippet answer: If there is an approved drug product containing zinc chloride, follow-on products typically enter via ANDA once reference listed and bioequivalence requirements apply. If the product is not systemically absorbed or is topical, the regulatory pathway can differ but still typically uses generic/505(j) frameworks when applicable.

Pathway-driven valuation differences

NDA market: pricing and barriers often reflect formulation and labeling
ANDA market: competition accelerates and margins compress unless patent barriers remain

What is the Orange Book status of zinc chloride in plastic container products?

Featured snippet answer: Orange Book status is determined by whether FDA lists drug products containing zinc chloride on a specific NDA and whether patents are listed for those NDCs.

How to convert Orange Book into an investment barrier map

A usable barrier map for zinc chloride packaging must capture:

Drug substance (zinc chloride)
Dosage form (solution/gel/other)
Container-closure (plastic composition and configuration)
Route of administration
Listed patents with expiration dates

If the Orange Book lists no patents for the exact NDC and container, the barrier is primarily:

Regulatory compliance, not IP

How strong is the patent estate for zinc chloride solutions or topical products?

Featured snippet answer: For known inorganic APIs, patent estates that matter are usually narrowly drafted around specific formulation and packaging compatibility, limiting enforcement breadth.

Strength scoring framework investors can apply

Score each listed patent by:

Claim scope: narrow vs broad
Multiple independent claims surviving validity challenges
Enablement and written description risk
Design-around feasibility (new plastic type, new excipients, different pH range)
Litigation history (if any) and claim construction outcomes

Likely result in zinc chloride commodities

Patent coverage tends to be narrower
Expected validity and design-around risk is higher
Net protection often compresses value

What patent litigation affects zinc chloride in plastic container products?

Featured snippet answer: Litigation risk is only material when a specific NDA-linked patent estate exists and is actively enforced. “Zinc chloride in plastic container” as a commodity description rarely maps to high-frequency litigation absent an NDA-specific patent holder.

Litigation risk drivers

Paragraph IV filings against listed patents
Injunction attempts
Settlement terms including “at-risk” launch timelines

Are there Paragraph IV challenges for zinc chloride packaged in plastic?

Featured snippet answer: Paragraph IV challenges require an ANDA with a Paragraph IV certification versus a listed Orange Book patent. Without a specific NDA/NDC record, no reliable count or names can be stated.

Investor interpretation

If Paragraph IV filings exist, the market is likely contestable and margin compression risk increases
If none exist, it may reflect either absence of Orange Book listings or weak commercial incentive

How does zinc chloride in plastic container compare with glass-container or blister-container zinc chloride products?

Featured snippet answer: If zinc chloride products are differentiated mainly by container-closure compatibility, switching container materials can be a primary basis for both patent claims and generic design-around.

Packaging as a competitive axis

Container selection can affect:

Extractables and leachables
Corrosion and discoloration
Stability (pH drift, precipitation)
Patient handling attributes (leak resistance, usability)

Design-around logic

If a patent claims a specific container material or liner, a generic may:

Use a different plastic grade
Change cap/liner
Modify packaging line process

What manufacturing/IP barriers exist for zinc chloride in plastic containers?

Featured snippet answer: The main barriers are GMP-grade process control for stability and container-closure compatibility, not chemistry-based IP.

Typical technical burden points

Controlled preparation of zinc chloride solutions to avoid impurities
pH and ionic strength control
Sterility assurance if intended for aseptic use
Stability testing in the exact container and closure configuration
Extractables/leachables and compatibility documentation

Revenue exposure and investment thesis: where margins come from

Featured snippet answer: Margin sustainability is typically tied to supply reliability, regulatory compliance, and packaging-specific stability performance rather than strong, long-lived IP.

Commercial model investors should use

Pricing power: usually low to moderate for commodity salts
Differentiation: stability, trace impurities, and packaging performance
Customer lock-in: dependent on qualification cycles (hospitals, wholesalers)
Volume growth: driven by substitution approvals and distribution agreements

Key takeaways

“Zinc chloride in plastic container” is likely an IP-light, packaging-and-compliance-dependent product category.
A defensible investment and patent-risk assessment requires mapping to a specific FDA-approved NDA/NDC record; otherwise, Orange Book and exclusivity cannot be tied to the exact product.
If Orange Book patents exist for the exact formulation and container configuration, value can come from narrow formulation/container claims. If not, generic and price compression risk is high.
Manufacturing and stability data tied to the container-closure system often function as the real barrier.

FAQs

Can a generic manufacturer launch zinc chloride packaged in plastic without challenging patents?
If the reference NDA has no listed patents for the relevant NDC/formulation/container, launches typically proceed without Paragraph IV risk; otherwise, IP barriers may require certification.
Do container-closure systems for zinc chloride generate enforceable IP?
They can, but claims are usually narrow to specific materials/liners/process steps and are design-around prone.
Is zinc chloride exclusivity likely to be tied to NCE status?
For inorganic zinc salts, NCE exclusivity is generally unlikely because the compound is not new.
Does topical vs oral use change the regulatory and patent landscape for zinc chloride?
Yes. Dosage form and route affect regulatory pathway and whether bioequivalence/clinical data requirements apply, which changes litigation and barrier dynamics.
What are the main diligence items for investors evaluating a zinc chloride plastic-container product?
FDA listing mapping (NDA/NDC), container-closure compatibility evidence, stability program in the exact packaging, and the completeness of any Orange Book patent listings tied to that NDC.

References (APA)

FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration.
FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
FDA. (n.d.). Paragraph IV certification and the Hatch-Waxman Amendments (general information). U.S. Food and Drug Administration.

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for ZINC CHLORIDE IN PLASTIC CONTAINER